Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
April 29, 2024 09:39 ET
|
Immix Biopharma, Inc.
European Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EUAccess to the EU centralized authorization procedureReduced fees for: EU...
Immix Biopharma on Track to Dose NXC-201 Patients in United States
April 18, 2024 09:32 ET
|
Immix Biopharma, Inc.
Scheduling U.S. site initiation visits April and May 2024On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New York City lead site and other leading U.S....
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
April 15, 2024 09:36 ET
|
Immix Biopharma, Inc.
Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory AL amyloidosis will be presented in Baltimore May 7-11, 2024 LOS ANGELES, April 15, 2024 (GLOBE NEWSWIRE) -- Immix...
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
March 20, 2024 09:46 ET
|
Immix Biopharma, Inc.
LOS ANGELES, CA, March 20, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell...
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
March 05, 2024 09:35 ET
|
Immix Biopharma, Inc.
LOS ANGELES, CA, March 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell...
Immix Biopharma 12 Month Review Progress Update
February 21, 2024 09:31 ET
|
Immix Biopharma, Inc.
LOS ANGELES, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its...
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
February 08, 2024 16:45 ET
|
Immix Biopharma, Inc.
LOS ANGELES, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies...
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
February 07, 2024 09:37 ET
|
Immix Biopharma, Inc.
European Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EUAccess to the EU centralized authorization procedureReduced fees for EU...
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
February 05, 2024 22:30 ET
|
Immix Biopharma, Inc.
LOS ANGELES, CA, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies...
Immix Biopharma Announces Proposed Public Offering of Common Stock
February 05, 2024 15:20 ET
|
Immix Biopharma, Inc.
LOS ANGELES, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (the “Company”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease,...